New York Biologics
New York Biologics Inc. has been providing material to the in-vitro diagnostic industry since 1993, with over 30 years of experience. The company supplies disease state samples, surplus blood products, and laboratory-derived products for research, development, and testing. They support the industry with a wide range of biospecimens, blood banking products, laboratory products, and analytical instrumentation, emphasizing quality, regulatory compliance, and personalized customer service. They have a strong focus on supporting COVID-19 research and diagnostics, maintaining IRB approvals and regulatory registrations. Their mission is to facilitate assay development and diagnostic research by providing high-quality biological samples and related services.
Industries
Nr. of Employees
small (1-50)
New York Biologics
Southampton, New York, United States, North America
Products
Blood bank-derived materials
Unit-sized materials derived from blood centers including whole blood, packed/red blood cell units (in-date and expired), source leukocytes, buffy coats, platelets, LRS chambers, positive plasma units and test-negative normal plasma/serum.
Laboratory-derived remnant specimens
De-identified, IRB-collected residual clinical specimens across infectious disease, oncology, chemistry, hematology, endocrine, immunology, toxicology, STD, respiratory pathogens, stool, swabs and other esoteric sample types; available fresh or frozen and accompanied by assay metadata.
Characterized biospecimen inventory (research marketplace)
Catalogued inventory of disease-state clinical specimens and laboratory-derived products intended to support IVD R&D, available to customize by marker, phenotype, age/gender and geographic region.
Blood bank-derived materials
Unit-sized materials derived from blood centers including whole blood, packed/red blood cell units (in-date and expired), source leukocytes, buffy coats, platelets, LRS chambers, positive plasma units and test-negative normal plasma/serum.
Laboratory-derived remnant specimens
De-identified, IRB-collected residual clinical specimens across infectious disease, oncology, chemistry, hematology, endocrine, immunology, toxicology, STD, respiratory pathogens, stool, swabs and other esoteric sample types; available fresh or frozen and accompanied by assay metadata.
Characterized biospecimen inventory (research marketplace)
Catalogued inventory of disease-state clinical specimens and laboratory-derived products intended to support IVD R&D, available to customize by marker, phenotype, age/gender and geographic region.
Services
Laboratory-managed method comparison and performance testing using remnant or supplied clinical specimens across multiple instrument platforms to evaluate systematic error and assay accuracy.
Laboratory-managed method comparison and performance testing using remnant or supplied clinical specimens across multiple instrument platforms to evaluate systematic error and assay accuracy.
Expertise Areas
- Biospecimen procurement and inventory management
- Remnant specimen collection under IRB protocols
- IVD sample supply for assay development and validation
- Method comparison and comparative method testing
Key Technologies
- Polymerase chain reaction (PCR) and real-time PCR
- Next-generation sequencing (NGS)
- Mass spectrometry (MS/MS)
- High-performance liquid chromatography (HPLC)